TG Therapeutics, Inc.

Historical 13F Holders

Symbol
TGTX
CUSIP
88322Q108
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 88322Q108 since 12/18/2024, newest first.

Filer % of Class Filed
Vanguard Portfolio Management LLC 13G 5.3% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 6 0% 3/27/2026
Event 3/13/2026
State Street Corp 13G 5.1% 11/10/2025
Event 9/30/2025
State Street Corp 13G 4.7% 5/13/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 6 12.8% 4/30/2025
Event 3/31/2025
Vanguard Group Inc 13G/A Amendment 5 10.0% 1/8/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 32 2.88 M $160 M
2026 Q2 469 121 M $6.27 B
2026 Q1 389 105 M $3.50 B
2025 Q4 376 103 M $3.08 B
2025 Q3 380 99.2 M $3.59 B
2025 Q2 391 102 M $3.68 B
2025 Q1 408 99.2 M $3.91 B
2024 Q4 366 97.2 M $2.93 B
2024 Q3 341 103 M $2.40 B
2024 Q2 289 95.5 M $1.71 B
2024 Q1 275 93.1 M $1.42 B
2023 Q4 273 94.1 M $1.61 B
2023 Q3 269 90.7 M $764 M
2023 Q2 286 88.4 M $2.19 B
2023 Q1 238 94.9 M $1.43 B
2022 Q4 227 104 M $1.23 B
2022 Q3 210 100 M $595 M
2022 Q2 201 107 M $454 M
2022 Q1 212 101 M $965 M
2021 Q4 229 102 M $1.93 B
2021 Q3 257 96.4 M $3.21 B
2021 Q2 263 96.2 M $3.73 B
2021 Q1 260 98.8 M $4.77 B
2020 Q4 277 100 M $5.23 B
2020 Q3 203 87.7 M $2.35 B
2020 Q2 198 84.0 M $1.63 B
2020 Q1 167 64.9 M $640 M
2019 Q4 159 59.3 M $658 M
2019 Q3 131 48.4 M $272 M
2019 Q2 142 50.4 M $436 M
2019 Q1 133 48.2 M $387 M
2018 Q4 129 49.6 M $204 M
2018 Q3 158 48.4 M $271 M
2018 Q2 151 40.8 M $536 M
2018 Q1 140 38.8 M $551 M
2017 Q4 118 35.8 M $293 M
2017 Q3 113 35.6 M $422 M
2017 Q2 115 34.3 M $345 M
2017 Q1 111 30.9 M $360 M
2016 Q4 97 21.8 M $101 M
2016 Q3 80 27.1 M $209 M
2016 Q2 94 29.1 M $178 M
2016 Q1 86 29.6 M $252 M
2015 Q4 93 26.9 M $321 M
2015 Q3 86 28.0 M $283 M
2015 Q2 94 23.9 M $396 M
2015 Q1 83 21.5 M $332 M
2014 Q4 80 18.7 M $296 M
2014 Q3 73 15.5 M $165 M
2014 Q2 74 13.1 M $123 M
2014 Q1 58 11.6 M $80.3 M